Efficacy of Shenqi Mai-Xin-Tong capsule on acute ischemic stroke and its effect on Lp-PLA2 and hs-CRP
Objective It is to evaluate the clinical efficacy of Shenqi Mai-Xin-Tong capsule in the treatment of acute is-chemic stroke and its effect on lipoprotein-associated phospholipase A2(Lp-PLA2)and high sensitive C-reactive protein(hs-CRP).Methods Seventy-two patients with acute ischemic stroke admitted to Guangzhou Hospital of Integrated Tradi-tional Chinese and Western Medicine from January to November 2022 were randomly divided into 36 patients in the treat-ment group and 36 patients in the control group.Both groups underwent conventional western medicine treatment,addition-ally,the treatment group was given Shenqi Mai-Xin-Tong capsule orally,totally treated for 12 weeks.The serum levels of Lp-PLA2 and hs-CRP,carotid intima-media thickness,and scores of National Institutes of Health Stroke Scale(NIHSS)of patients in the two groups before and after treatment were compared,the clinical efficacy and the efficacy of carotid intima-media thickness of the two groups were assessed,the percentage of patients with daily living ability Barthel index≥75,and the percentage of patients with modified Rankin Scale(mRS)scores≤2 were calculated,and the safety of treatment in the two groups was also evaluated.Results Both 30 cases in the treatment and control groups completed the study.After treatment,the serum levels of Lp-PLA2 and hs-CRP,carotid intima-media thickness and NIHSS scores in the treatment group were significantly lower than those before treatment and in the control groups(all P＜0.05),and only serum level of Lp-PLA2 and NIHSS scores were significantly lower than those before treatment in the control group(both P＜0.05).The total clinical effective rate of the treatment group and control group were 86.7%(26/30)and 63.3%(19/30),respec-tively,and the total effective rate of carotid intima-media thickness treatment was66.7%(20/30)and40.0%(12/30),respectively,and the differences between the two groups were statistically significant(all P＜0.05).The percentage of pa-tients with daily living ability Barthel index≥75 and that of patients with mRS score≤2 were63.3%(19/30)and73.3%(22/30)in the treatment group and 33.3%(10/30)and 46.7%(14/30)in the control group,respectively,and the differences between the two groups were statistically significant(all P＜0.05).No significant adverse reactions occurred in the two groups.Conclusion Shenqi Mai-Xin-Tong capsule can significantly reduce serum levels of Lp-PLA2 and hs-CRP and plaque size in patients with acute ischemic stroke,which can contribute to neurological rehabilitation and improvement of prognosis.
万方数据
维普
